Alector, Inc.
Every calculator, already run for ALEC
Open the full toolkit →You have the numbers on ALEC. Get the argument.
A written report on which of these readings actually decide the outcome for Alector, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
7 analysts covering ALECAnalyst Price Target Disagreement for Alector, Inc.
Wall Street's bull case implies +213% from the current price; the bear case implies -48%. A 260% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ALEC
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Alector, Inc.
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Al…
ALEC — frequently asked
Is ALEC a buy right now?
Wall Street's consensus rating on Alector, Inc. is Hold across 7 analysts, with a mean price target of $3.10 (+61% vs. the current $1.92). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is ALEC's next earnings date?
Alector, Inc. is next scheduled to report earnings around Nov 5, 2026. A full ALEC research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Alector, Inc.?
Analysts covering Alector, Inc. (ALEC) range from a bear-case target of $1.00 to a bull-case high of $6.00, with a mean consensus target of $3.10 across 5 analysts. The spread of $5.00 (260% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Alector, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Alector, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ALEC research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Alector, Inc., in minutes. 3 free reports included with every account — no credit card required.